- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06188689
Evaluatie van een klinische diagnostische test voor CRDS (DIAGNOSE CRDS)
Evaluatie van een klinische diagnostische test voor het calciumvrijgavedeficiëntiesyndroom: de DIAGNOSE CRDS-studie
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
RyR2 loss-of-function variants have recently been established as causative for a new disease termed calcium release deficiency syndrome (CRDS) that confers a risk of malignant ventricular arrhythmias and sudden cardiac death. RyR2 encodes the cardiac ryanodine receptor, the calcium release channel on the sarcoplasmic reticulum that mediates excitation-contraction coupling through calcium-induced calcium-release. In contrast to CRDS, pathogenic RyR2 gain-of-function variants result in an autosomal dominant form of catecholaminergic polymorphic ventricular tachycardia (CPVT). The adrenergic-mediated ventricular arrhythmias characteristic of CPVT can be readily reproduced on exercise stress testing (EST), making EST the standard clinical diagnostic tool for CPVT.
In contrast to CPVT, the CRDS clinical phenotype is concealed with standard cardiac testing tools and its diagnosis presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. Beyond the significant time delay associated with in vitro functional analysis, this testing requires specialized expertise that is not widely available and remains research-based, making it impractical for routine use in clinical care. In this overall context, it is likely that the vast majority of global CRDS cases have yet to be diagnosed.
A prior report of an "atypical CPVT" family carrying an RyR2-p.M4109R variant observed marked and transient repolarization changes following pacing mediated tachycardia and a subsequent pause. Since publication of this report, in vitro characterization of the RyR2-p.M4109R variant has confirmed its being loss-of-function and the familial diagnosis has been revised to CRDS. Driven by these observations and promising preliminary findings, the DIAGNOSE CRDS study seeks to further investigate this apparent electrocardiographic signature of CRDS following brief tachycardia and subsequent pause as a potential method to clinically diagnose the condition.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jason Roberts, MD MAS
- Telefoonnummer: 40632 905-297-3479
- E-mail: jason.roberts@phri.ca
Studie Locaties
-
-
-
Brussels, België, 1090
- Werving
- Universitair Ziekenhuis Brussel
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Luigi Pannone, MD
-
-
Antwerp
-
Edegem, Antwerp, België, 2650
- Werving
- Antwerp University Hospital
-
Hoofdonderzoeker:
- Johan Saenen, MD, PhD
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- Werving
- University of Calgary
-
Hoofdonderzoeker:
- Erkan Ilhan, MD
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Edmonton, Alberta, Canada, T6G 2C8
- Werving
- Alberta Health Services
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Joseph Atallah, MD CM, MSc
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Werving
- The University of British Columbia
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Thomas M Roston, MD
-
Vancouver, British Columbia, Canada, V6H 3N1
- Werving
- Children's & Women's Health Centre of British Columbia
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Shubhayan Sanatani, MD
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Werving
- Hamilton General Hospital
-
Hoofdonderzoeker:
- Jason D Roberts, MD MAS
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
London, Ontario, Canada, N6A 5A5
- Werving
- London Health Sciences Centre - University Hospital
-
Hoofdonderzoeker:
- Habib R Khan, MD
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ottawa, Ontario, Canada, K1Y 4W7
- Werving
- Ottawa Heart Institute
-
Hoofdonderzoeker:
- Simon Hansom, MD
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Toronto, Ontario, Canada, M5G 2C4
- Werving
- Toronto General Hospital
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Michael H. Gollob, MD, FRCP(C)
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Werving
- Montréal Heart Institute
-
Hoofdonderzoeker:
- Rafik Tadros, MD PhD
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Québec, Quebec, Canada, G1V 4G5
- Werving
- Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval
-
Hoofdonderzoeker:
- Christian Steinberg, MD
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
-
Aarhus, Denemarken, DK-8200 N
- Werving
- Aarhus University Hospital
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Henrik Jensen, MD
-
-
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankrijk, 33404
- Werving
- CHU de Bordeaux
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Frédéric Sacher, MD
-
-
-
-
-
Jerusalem, Israël, 9103102
- Werving
- Shaare Zedek Medical Center
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Ziv Dadon, MD
-
-
-
-
London
-
London, London, Verenigd Koninkrijk, WC1N 3JH
- Werving
- Great Ormond Street Hospital
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Luke Starling, BSc (Hons), MB BS, FRCPCH
-
-
Oxfordshire
-
Oxford, Oxfordshire, Verenigd Koninkrijk, OX3 9DU
- Werving
- Oxford University Hospitals
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Julian Ormerod, BM, Bch, FRCP
-
-
-
-
California
-
San Francisco, California, Verenigde Staten, 94143
- Werving
- University of California
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Vasanth Vedantham, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Werving
- Boston Children's Hospital
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Dominic Abrams, MBBS, MD, MBA
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- John Giudicessi, MD, PhD
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98195
- Werving
- University of Washington
-
Contact:
- Project Manager
- Telefoonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Hoofdonderzoeker:
- Uyanga Batnyam, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases
Inclusion criteria:
• Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing
Exclusion criteria:
• Unable to provide informed consent
Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases
Inclusion criteria:
- Satisfy a clinical phenotype consistent with the Expert Consensus Statement
- Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants
Exclusion criteria:
- Unable to provide informed consent
- Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers
Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA)
Inclusion criteria:
- Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
- Undergone genetic testing that includes screening of RyR2*
Exclusion criteria:
-
Unable to provide informed consent
-
Use of a QT prolonging medication at the time of the burst pacing maneuvers
- Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary).
Cohort 4: SVT controls
Inclusion criteria:
• Undergoing an invasive electrophysiology study
Exclusion criteria:
- Ventricular cardiomyopathy
- Ventricular pre-excitation
- Long QT syndrome
- Use of a QT prolonging medication at the time of the EP study
- Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study
- Known obstructive coronary artery disease (existing coronary stenosis >50%)
- Unable to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Pacing
Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated. |
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
ΔT-wave amplitude value
Tijdsspanne: At time of pacing maneuver
|
T-wave amplitude on first post-pause sinus beat subtracted by the T-wave amplitude on the last sinus beat prior to pacing |
At time of pacing maneuver
|
|
ΔQT value
Tijdsspanne: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat subtracted by the absolute QT value on the last sinus beat prior to pacing |
At time of pacing maneuver
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Absolute QT value
Tijdsspanne: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat |
At time of pacing maneuver
|
|
Absolute T-wave amplitude
Tijdsspanne: At time of pacing maneuver
|
Absolute T-wave amplitude on first post-pause sinus beat |
At time of pacing maneuver
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie directeur: Ziv Dadon, MD, Shaare Zedek Medical Center
- Hoofdonderzoeker: Jason D Roberts, MD MAS, McMaster University
- Hoofdonderzoeker: Wayne Chen, PhD, University of Calgary
Publicaties en nuttige links
Algemene publicaties
- Sun B, Yao J, Ni M, Wei J, Zhong X, Guo W, Zhang L, Wang R, Belke D, Chen YX, Lieve KVV, Broendberg AK, Roston TM, Blankoff I, Kammeraad JA, von Alvensleben JC, Lazarte J, Vallmitjana A, Bohne LJ, Rose RA, Benitez R, Hove-Madsen L, Napolitano C, Hegele RA, Fill M, Sanatani S, Wilde AAM, Roberts JD, Priori SG, Jensen HK, Chen SRW. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med. 2021 Feb 3;13(579):eaba7287. doi: 10.1126/scitranslmed.aba7287.
- Nof E, Belhassen B, Arad M, Bhuiyan ZA, Antzelevitch C, Rosso R, Fogelman R, Luria D, El-Ani D, Mannens MM, Viskin S, Eldar M, Wilde AA, Glikson M. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm. 2011 Oct;8(10):1546-52. doi: 10.1016/j.hrthm.2011.05.016. Epub 2011 May 26.
- Ormerod JOM, Ormondroyd E, Li Y, Taylor J, Wei J, Guo W, Wang R, Sarton CNS, McGuire K, Dreau HMP, Taylor JC, Ginks MR, Rajappan K, Chen SRW, Watkins H. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022 Feb;15(1):e003589. doi: 10.1161/CIRCGEN.121.003589. Epub 2021 Dec 24.
- Roston TM, Wei J, Guo W, Li Y, Zhong X, Wang R, Estillore JP, Peltenburg PJ, Noguer FRI, Till J, Eckhardt LL, Orland KM, Hamilton R, LaPage MJ, Krahn AD, Tadros R, Vinocur JM, Kallas D, Franciosi S, Roberts JD, Wilde AAM, Jensen HK, Sanatani S, Chen SRW. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458.
- Ni M, Dadon Z, Ormerod JOM, Saenen J, Hoeksema WF, Antiperovitch P, Tadros R, Christiansen MK, Steinberg C, Arnaud M, Tian S, Sun B, Estillore JP, Wang R, Khan HR, Roston TM, Mazzanti A, Giudicessi JR, Siontis KC, Alak A, Acosta JG, Divakara Menon SM, Tan NS, van der Werf C, Nazer B, Vivekanantham H, Pandya T, Cunningham J, Gula LJ, Wong JA, Amit G, Scheinman MM, Krahn AD, Ackerman MJ, Priori SG, Gollob MH, Healey JS, Sacher F, Nof E, Glikson M, Wilde AAM, Watkins H, Jensen HK, Postema PG, Belhassen B, Chen SRW, Roberts JD. A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. JAMA. 2024 Jul 16;332(3):204-213. doi: 10.1001/jama.2024.8599.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 14546
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .